Dongguang Wei

Dr. Dongguang Wei

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2006 in Developmental Neurobiology
Verified
Journal Article
Closed access
PDF file
DWDongguang Wei
Dongguang Wei
ZJZhe Jin
Zhe Jin
LJLeif Järlebark
Leif Järlebark
ESEric Scarfone
Eric Scarfone
MUMats Ulfendahl
Mats Ulfendahl

30 December 2008 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
DWDongguang Wei
Dongguang Wei
SLSnezana Levic
Snezana Levic
LNLiping Nie
Liping Nie
WGWei-Qiang Gao
Wei-Qiang Gao
CPChristine Petit
Christine Petit
EYEbenezer N. Yamoah
Ebenezer N. Yamoah
Auditory hair cell defect is a major cause of hearing impairment, often leading to spiral ganglia neuron (SGN) degeneration. The cell loss that follows is irreversible in mammals, because inner ear hair cells (HCs) have a limited capacity to regenerate. Here, we report that in the adult brain of both rodents and humans, the ependymal layer of the lateral ventricle contains cells with proliferative potential, which share morphological and functional characteristics with HCs. In addition, putative neural stem cells (NSCs) from the subventricular zone of the lateral ventricle can differentiate into functional SGNs. Also important, the NSCs can incorporate into the sensory epithelia, demonstrating their therapeutic potential. We assert that NSCs and edendymal cells can undergo an epigenetic functional switch to assume functional characteristics of HCs and SGNs. This study suggests that the functional plasticity of renewable cells and conditions that promote functional reprogramming can be used for cell therapy in the auditory setting.

28 November 2022 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
TTTed W. Toal
Ted W. Toal
AEAna P. Estrada-Florez
Ana P. Estrada-Florez
GPGuadalupe M. Polanco-Echeverry
Guadalupe M. Polanco-Echeverry
RSRuta M. Sahasrabudhe
Ruta M. Sahasrabudhe
PLPaul C. Lott
Paul C. Lott
LCLuis Carvajal-Carmona
Luis Carvajal-Carmona
Gastric cancer is a leading cause of cancer mortality and health disparities in Latinos. We evaluated gastric intratumoral heterogeneity using multiregional sequencing of >700 cancer genes in 115 tumor biopsies from 32 patients, 29 who were Latinos. Analyses focused on comparisons with The Cancer Genome Atlas (TCGA) and on mutation clonality, druggability, and signatures. We found that only approximately 30% of all mutations were clonal and that only 61% of the known TCGA gastric cancer drivers harbored clonal mutations. Multiple clonal mutations were found in new candidate gastric cancer drivers such as EYS, FAT4, PCDHA1, RAD50, EXO1, RECQL4, and FSIP2. The genomically stable (GS) molecular subtype, which has the worse prognosis, was identified in 48% of our Latino patients, a fraction that was >2.3-fold higher than in TCGA Asian and White patients. Only a third of all tumors harbored clonal pathogenic mutations in druggable genes, with most (93%) GS tumors lacking actionable clonal mutations. Mutation signature analyses revealed that, in microsatellite-stable (MSS) tumors, DNA repair mutations were common for both tumor initiation and progression, while tobacco, POLE, and inflammation signatures likely initiate carcinogenesis. MSS tumor progression was likely driven by aging- and aflatoxin-associated mutations, as these latter changes were usually nonclonal. In microsatellite-unstable tumors, nonclonal tobacco-associated mutations were common. Our study, therefore, contributed to advancing gastric cancer molecular diagnostics and suggests clonal status is important to understanding gastric tumorigenesis. Our findings of a higher frequency of a poor prognosis associated molecular subtype in Latinos and a possible new aflatoxin gastric cancer etiology also advance cancer disparities research.Significance: Our study contributes to advancing our knowledge of gastric carcinogenesis, diagnostics, and cancer health disparities.

1 September 2017 in Archives of Pathology & Laboratory Medicine
Verified
Journal Article
Closed access
ASAdam L. Booth, MD1; Diana Rodgers, MD2; Phillip Osehobo, MD, PhD2; Lalarukh K. Aftab, MD3; Mahmoud A. Eltorky, MD2; Heather L. Stevenson, MD, PhD11Department of Pathology, University of Texas Medical Branch, Galveston2Department of Pathology, WellStar Spa
Adam L. Booth, MD1; Diana Rodgers, MD2; Phillip Osehobo, MD, PhD2; Lalarukh K. Aftab, MD3; Mahmoud A. Eltorky, MD2; Heather L. Stevenson, MD, PhD11Department of Pathology, University of Texas Medical Branch, Galveston2Department of Pathology, WellStar Spa
ABAdam L. Booth
Adam L. Booth
DRDiana Rodgers
Diana Rodgers
POPhillip Osehobo
Phillip Osehobo
LALalarukh K. Aftab
Lalarukh K. Aftab
YSYing Liu, MD, PhD; Lynne Opitz, MD; Guo-Xia Tong, MD, PhDDepartment of Pathology and Laboratory Medicine, Staten Island University Hospital, Sta
Ying Liu, MD, PhD; Lynne Opitz, MD; Guo-Xia Tong, MD, PhDDepartment of Pathology and Laboratory Medicine, Staten Island University Hospital, Sta
Article Citation: (2017) Abstracts and Case Studies From the College of American Pathologists 2017 Annual Meeting (CAP17). Archives of Pathology & Laboratory Medicine: September 2017, Vol. 141, No. 9, pp. e2-e191. https://doi.org/10.5858/arpa.2017-0238-AB
1

27 September 2024 in Cancers
Verified
Journal Article
Open access
PDF file
MTMehran Taherian
Mehran Taherian
MKMatthew H. G. Katz
Matthew H. G. Katz
LPLaura Prakash
Laura Prakash
DWDongguang Wei
Dongguang Wei
YTYi Tat Tong
Yi Tat Tong
HWHuamin Wang
Huamin Wang
Adequate sampling is essential to an accurate pathologic evaluation of pancreatectomy specimens resected for pancreatic ductal adenocarcinoma (PDAC) after neoadjuvant therapy (NAT). However, limited data are available for the association between the sampling and survival in these patients. We examined the association of the entire submission of the tumor (ESOT) and the entire submission of the pancreas (ESOP) with disease-free survival (DFS) and overall survival (OS), as well as their correlations with clinicopathologic features, for 627 patients with PDAC who received NAT and pancreaticoduodenectomy. We demonstrated that both ESOT and ESOP were associated with lower ypT, less frequent perineural invasion, and better tumor response (p < 0.05). ESOP was also associated with a smaller tumor size (p < 0.001), more lymph nodes (p < 0.001), a lower ypN stage (p < 0.001), better differentiation (p = 0.02), and less frequent lymphovascular invasion (p = 0.009). However, since ESOP and ESOT were primarily conducted for cases with no grossly identifiable tumor or minimal residual carcinoma in initial sections, potential bias cannot be excluded. Both ESOT and ESOP were associated with less frequent recurrence/metastasis and better DFS and OS (p < 0.05) in the overall study population. ESOP was associated with better DFS and better OS in patients with ypT0/ypT1 or ypN0 tumors and better OS in patients with complete or near-complete response (p < 0.05). ESOT was associated with better OS in patients with ypT0/ypT1 or ypN0 tumors (p < 0.05). Both ESOT and ESOP were independent prognostic factors for OS according to multivariate survival analyses. Therefore, accurate pathologic evaluation using ESOP and ESOT is associated with the prognosis in PDAC patients with complete or near-complete pathologic response and ypT0/ypT1 tumor after NAT.

4 April 2023
Verified
Other
Open access
TTTed W. Toal
Ted W. Toal
AEAna P. Estrada-Florez
Ana P. Estrada-Florez
GPGuadalupe M. Polanco-Echeverry
Guadalupe M. Polanco-Echeverry
RSRuta M. Sahasrabudhe
Ruta M. Sahasrabudhe
PLPaul C. Lott
Paul C. Lott
LCLuis Carvajal-Carmona
Luis Carvajal-Carmona
PDF file of supplementary methods and materials, and supplementary figures and tables